Huons Meditech CI. (Image=Huons Meditech)
Huons Meditech announced on the 10th its participation in ‘World Health Expo Dubai 2026 (WHX Dubai 2026)’, held from February 9 to 12 in Dubai, UAE.
As the largest healthcare exhibition in the Middle East, ‘WHX Dubai’ brings together medical device companies, buyers and healthcare professionals from across the Middle East, Africa, Europe and Asia to share the latest technologies and industry trends.
Huons Meditech unveiled a wide range of flagship products across urology, aesthetics and infection control at the exhibition. In the urology segment, the company introduced “URO-UEMXD” the first domestically developed extracorporeal shock wave lithotripter that combines a shock wave head and ultrasound in an in line structure.
This innovation enables more intuitive and precise stone localization and treatment, enhancing clinical efficiency for medical professionals.
In aesthetics, Huons Meditech showcased its mesotherapy injector, “DermaShine Pro” alongside the newly launched “DermaShine Duo_RF”.
DermaShine Pro recognized globally for its precise drug delivery performance and user-friendly interface once again drew strong interest at WHX Dubai. The company also emphasized the importance of using genuine needles through a global campaign, highlighting safety and quality assurance.
Debuting for the first time at an international exhibition DermaShine Duo_RF integrates advanced drug delivery with low energy radiofrequency (RF) technology, offering a hybrid solution that combines injectable treatments with skin tightening in a single device.
In infection control Huons Meditech presented its endoscope washer disinfector DR-02, providing hospitals and clinics with effective solutions for infection prevention and efficient device management.
Changwoo Ha (CEO of Huons Meditech) stated “Participating in WHX Dubai 2026 allowed us to effectively showcase Huons Meditech’s technological strengths and product competitiveness to the global market. We will continue to drive innovation and enhance quality across aesthetics urology and infection control to strengthen our position as a global medical device company.”









